Skip to main content
SpringerLink
Log in

Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia

  • Review
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale and background

The development of atypical antipsychotic (AAP) drugs has brought about dramatic improvement in the function of many patients with schizophrenia and related mental disorders. However, prescription of AAPs is frequently associated with the emergence of weight gain, hypertriglyceridemia, and other metabolic disturbances. Although the mechanisms involved in AAP-induced hypertriglyceridemia remain to be fully elucidated, several studies have proposed that this side effect may be associated with weight gain and obesity. Recently, special emphasis has been placed on the evidence indicating a direct effect of AAPs on triglyceride metabolism.

Objectives

In this review, we highlight recent findings discussing the potential mechanisms by which AAPs may contribute to hypertriglyceridemia. In addition, we summarize the adjunctive pharmacologic treatments for AAP-associated dyslipidemia.

Conclusions

There is evidence that AAPs may cause hypertriglyceridemia through several possible mechanisms: (1) a direct effect on triglyceride metabolism either by stimulation of hepatic triglyceride production and secretion or by inhibition of lipoprotein lipase-mediated triglyceride hydrolysis and (2) an indirect mechanism associated with obesity and insulin resistance. The practical applications of this manuscript provide new insights for the future investigation of AAPs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adachi H, Yanai H, Hirowatari Y (2012) The underlying mechanisms for olanzapine-induced hypertriglyceridemia. J Clin Med Res 4:206–208

    PubMed  CAS  Google Scholar 

  • Adiels M, Boren J, Caslake MJ, Stewart P, Soro A, Westerbacka J, Wennberg B, Olofsson SO, Packard C, Taskinen MR (2005) Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 25:1697–1703

    Article  PubMed  CAS  Google Scholar 

  • Amemiya-Kudo M, Shimano H, Hasty AH, Yahagi N, Yoshikawa T, Matsuzaka T, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Sato R, Kimura S, Ishibashi S, Yamada N (2002) Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes. J Lipid Res 43:1220–1235

    PubMed  CAS  Google Scholar 

  • Arulmozhi DK, Dwyer DS, Bodhankar SL (2006) Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice. Life Sci 79:1865–1872

    Article  PubMed  CAS  Google Scholar 

  • Atmaca M, Kuloglu M, Tezcan E, Ustundag B (2003) Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 64:598–604

    Article  PubMed  CAS  Google Scholar 

  • Baptista T, Uzcategui E, Rangel N, El Fakih Y, Galeazzi T, Beaulieu S, de Baptista EA (2008) Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Res 159:250–253

    Article  PubMed  CAS  Google Scholar 

  • Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U (2003) Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 11:556–562

    Article  PubMed  CAS  Google Scholar 

  • Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA, Friis S, Opjordsmoen S, Andreassen OA (2008) Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 28:132–137

    Article  PubMed  CAS  Google Scholar 

  • Bishop JR, Stanford KI, Esko JD (2008) Heparan sulfate proteoglycans and triglyceride-rich lipoprotein metabolism. Curr Opin Lipidol 19:307–313

    Article  PubMed  CAS  Google Scholar 

  • Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM (2010) Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci 31:484–497

    Article  PubMed  CAS  Google Scholar 

  • Brown MS, Goldstein JL (2008) Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 7:95–96

    Article  PubMed  CAS  Google Scholar 

  • Buckley PF (2001) Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 50:912–924

    Article  PubMed  CAS  Google Scholar 

  • Chao PM, Kuo YH, Lin YS, Chen CH, Chen SW (2010) The metabolic benefits of Polygonum hypoleucum Ohwi in HepG2 cells and Wistar rats under lipogenic stress. J Agric Food Chem 58:5174–5180

    Article  PubMed  CAS  Google Scholar 

  • Chen CH, Chiu CC, Huang MC, Wu TH, Liu HC, Lu ML (2008) Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 32:925–931

    Article  PubMed  CAS  Google Scholar 

  • Coccurello R, Moles A (2010) Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther 127:210–251

    Article  PubMed  CAS  Google Scholar 

  • De Hert M, Kalnicka D, van Winkel R, Wampers M, Hanssens L, Van Eyck D, Scheen A, Peuskens J (2006) Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 67:1889–1896

    Article  PubMed  Google Scholar 

  • de Leon J, Correa JC, Ruano G, Windemuth A, Arranz MJ, Diaz FJ (2008) Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophr Res 98:40–46

    Article  PubMed  Google Scholar 

  • de Leon J, Diaz FJ (2007) Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy. Schizophr Res 96:185–197

    Article  PubMed  Google Scholar 

  • Diaz FJ, Meary A, Arranz MJ, Ruano G, Windemuth A, de Leon J (2009) Acetyl-coenzyme A carboxylase alpha gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels. Schizophr Res 115:136–140

    Article  PubMed  Google Scholar 

  • Eckel RH (1989) Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 320:1060–1068

    Article  PubMed  CAS  Google Scholar 

  • Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M, Kemmler G, Lechleitner M, Fleischhacker WW (2001) Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 158:1719–1722

    Article  PubMed  CAS  Google Scholar 

  • Ferno J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ, Breilid H, Lovlie R, Berge RK, Stansberg C, Steen VM (2005) Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J 5:298–304

    Article  PubMed  CAS  Google Scholar 

  • Fukuen S, Iwaki M, Yasui A, Makishima M, Matsuda M, Shimomura I (2005) Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J Biol Chem 280:23653–23659

    Article  PubMed  CAS  Google Scholar 

  • Harwood HJ Jr (2005) Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. Expert Opin Ther Targets 9:267–281

    Article  PubMed  CAS  Google Scholar 

  • Hemmrich K, Gummersbach C, Pallua N, Luckhaus C, Fehsel K (2006) Clozapine enhances differentiation of adipocyte progenitor cells. Mol Psychiatry 11:980–981

    Article  PubMed  CAS  Google Scholar 

  • Hong CJ, Chen TT, Bai YM, Liou YJ, Tsai SJ (2011) Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment. World J Biol Psychiatry 13:22–29

    Article  PubMed  Google Scholar 

  • Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109:1125–1131

    PubMed  CAS  Google Scholar 

  • Joy CB, Mumby-Croft R, Joy LA (2006) Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev: CD001257

  • Karasawa T, Takahashi A, Saito R, Sekiya M, Igarashi M, Iwasaki H, Miyahara S, Koyasu S, Nakagawa Y, Ishii K, Matsuzaka T, Kobayashi K, Yahagi N, Takekoshi K, Sone H, Yatoh S, Suzuki H, Yamada N, Shimano H (2011) Sterol regulatory element-binding protein-1 determines plasma remnant lipoproteins and accelerates atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 31:1788–1795

    Article  PubMed  CAS  Google Scholar 

  • Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, Revicki D, Buchanan RW (2002) An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 59:1021–1026

    Article  PubMed  CAS  Google Scholar 

  • Landry P, Dimitri E, Tessier S, Legare N (2008) Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study. J Clin Psychopharmacol 28:348–349

    Article  PubMed  Google Scholar 

  • Lauressergues E, Staels B, Valeille K, Majd Z, Hum DW, Duriez P, Cussac D (2010) Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes. Naunyn Schmiedebergs Arch Pharmacol 381:427–439

    Article  PubMed  CAS  Google Scholar 

  • Markham-Abedi C, de Leon J (2006) Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report. J Clin Psychiatry 67:1473–1474

    Article  PubMed  Google Scholar 

  • Mauriege P, Marette A, Atgie C, Bouchard C, Theriault G, Bukowiecki LK, Marceau P, Biron S, Nadeau A, Despres JP (1995) Regional variation in adipose tissue metabolism of severely obese premenopausal women. J Lipid Res 36:672–684

    PubMed  CAS  Google Scholar 

  • Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, Laatsch A, Heeren J (2005) Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 280:21553–21560

    Article  PubMed  CAS  Google Scholar 

  • Meyer JM (2001a) Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 62(Suppl 27):27–34, discussion 40-41

    PubMed  CAS  Google Scholar 

  • Meyer JM (2001b) Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 21:369–374

    Article  PubMed  CAS  Google Scholar 

  • Meyer JM (2002) A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 63:425–433

    Article  PubMed  CAS  Google Scholar 

  • Meyer JM, Koro CE (2004) The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70:1–17

    Article  PubMed  Google Scholar 

  • Minet-Ringuet J, Even PC, Valet P, Carpene C, Visentin V, Prevot D, Daviaud D, Quignard-Boulange A, Tome D, de Beaurepaire R (2007) Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol Psychiatry 12:562–571

    Article  PubMed  CAS  Google Scholar 

  • Mitrou P, Boutati E, Lambadiari V, Maratou E, Komesidou V, Papakonstantinou A, Sidossis L, Tountas N, Katsilambros N, Economopoulos T, Raptis SA, Dimitriadis G (2010) Rates of lipid fluxes in adipose tissue in vivo after a mixed meal in morbid obesity. Int J Obes (Lond) 34:770–774

    Article  CAS  Google Scholar 

  • Moon YA, Liang G, Xie X, Frank-Kamenetsky M, Fitzgerald K, Koteliansky V, Brown MS, Goldstein JL, Horton JD (2012) The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab 15:240–246

    Article  PubMed  CAS  Google Scholar 

  • Nagamine T (2008) Olanzapine-induced elevation of serum triglyceride levels in a normal weight patient with schizophrenia. Intern Med 47:181–182

    Article  PubMed  Google Scholar 

  • Narula PK, Rehan HS, Unni KE, Gupta N (2010) Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res 118:218–223

    Article  PubMed  Google Scholar 

  • Newall H, Myles N, Ward PB, Samaras K, Shiers D, Curtis J (2012) Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. Int Clin Psychopharmacol 27:69–75

    Article  PubMed  Google Scholar 

  • Oh KJ, Park J, Lee SY, Hwang I, Kim JB, Park TS, Lee HJ, Koo SH (2011) Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism. Am J Physiol Endocrinol Metab 300:E624–E632

    Article  PubMed  CAS  Google Scholar 

  • Ojala K, Repo-Tiihonen E, Tiihonen J, Niskanen L (2008) Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents. J Psychopharmacol 22:33–38

    Article  PubMed  CAS  Google Scholar 

  • Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ (2006) Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 163:1821–1825

    Article  PubMed  Google Scholar 

  • Panarotto D, Remillard P, Bouffard L, Maheux P (2002) Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue-specific manner. Eur J Clin Invest 32:84–92

    Article  PubMed  CAS  Google Scholar 

  • Pavan C, Vindigni V, Michelotto L, Rimessi A, Abatangelo G, Cortivo R, Pinton P, Zavan B (2010) Weight gain related to treatment with atypical antipsychotics is due to activation of PKC-beta. Pharmacogenomics J 10:408–417

    Article  PubMed  CAS  Google Scholar 

  • Peet M, Horrobin DF (2002) A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 36:7–18

    Article  PubMed  Google Scholar 

  • Perez-Iglesias R, Mata I, Pelayo-Teran JM, Amado JA, Garcia-Unzueta MT, Berja A, Martinez-Garcia O, Vazquez-Barquero JL, Crespo-Facorro B (2009) Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naive population. Schizophr Res 107:115–121

    Article  PubMed  Google Scholar 

  • Potts JL, Coppack SW, Fisher RM, Humphreys SM, Gibbons GF, Frayn KN (1995) Impaired postprandial clearance of triacylglycerol-rich lipoproteins in adipose tissue in obese subjects. Am J Physiol 268:E588–E594

    PubMed  CAS  Google Scholar 

  • Raeder MB, Ferno J, Vik-Mo AO, Steen VM (2006) SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects? Mol Cell Biochem 289:167–173

    Article  PubMed  CAS  Google Scholar 

  • Reaven GM, Lieberman JA, Sethuraman G, Kraemer H, Davis JM, Blasey C, Tsuang MT, Schatzberg AF (2009) In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. J Psychiatr Res 43:997–1002

    Article  PubMed  Google Scholar 

  • Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL (2000) Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 6:77–86

    PubMed  CAS  Google Scholar 

  • Shin L, Bregman H, Breeze JL, Noyes N, Frazier JA (2009) Metformin for weight control in pediatric patients on atypical antipsychotic medication. J Child Adolesc Psychopharmacol 19:275–279

    Article  PubMed  Google Scholar 

  • Sinn N, Milte C, Howe PR (2010) Oiling the brain: a review of randomized controlled trials of omega-3 fatty acids in psychopathology across the lifespan. Nutrients 2:128–170

    Article  PubMed  CAS  Google Scholar 

  • Skrede S, Ferno J, Vazquez MJ, Fjaer S, Pavlin T, Lunder N, Vidal-Puig A, Dieguez C, Berge RK, Lopez M, Steen VM (2012) Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int J Neuropsychopharmacol 15:163–179

    Article  PubMed  CAS  Google Scholar 

  • Smith RC, Segman RH, Golcer-Dubner T, Pavlov V, Lerer B (2008) Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Pharmacogenomics J 8:228–236

    Article  PubMed  CAS  Google Scholar 

  • Sparks JD, Sparks CE, Adeli K (2012) Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler Thromb Vasc Biol 32:2104–2112

    Article  PubMed  CAS  Google Scholar 

  • Subramanian S, Chait A (2012) Hypertriglyceridemia secondary to obesity and diabetes. Biochim Biophys Acta 1821:819–825

    Article  PubMed  CAS  Google Scholar 

  • van de Woestijne AP, Monajemi H, Kalkhoven E, Visseren FL (2011) Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management. Obes Rev 12:829–840

    Article  PubMed  Google Scholar 

  • Vestri HS, Maianu L, Moellering DR, Garvey WT (2007) Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 32:765–772

    Article  PubMed  CAS  Google Scholar 

  • Victoriano M, de Beaurepaire R, Naour N, Guerre-Millo M, Quignard-Boulange A, Huneau JF, Mathe V, Tome D, Hermier D (2010) Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state. Brain Res 1350:167–175

    Article  PubMed  CAS  Google Scholar 

  • Vik-Mo AO, Birkenaes AB, Ferno J, Jonsdottir H, Andreassen OA, Steen VM (2008) Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int J Neuropsychopharmacol 11:679–684

    Article  PubMed  CAS  Google Scholar 

  • Vincenzi B, Borba CP, Gray DA, Copeland PM, Wang X, Fan X, Aragam GG, Henderson DC (2013) An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics. Ann Clin Psychiatry 25:141–148

    PubMed  Google Scholar 

  • Wang CS, McConathy WJ, Kloer HU, Alaupovic P (1985) Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III J Clin Invest 75:384–390

    Article  CAS  Google Scholar 

  • Weiden PJ, Daniel DG, Simpson G, Romano SJ (2003) Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 23:595–600

    Article  PubMed  CAS  Google Scholar 

  • Wetterling T, Schneider B, Weber B (2007) Dyslipidemia and schizophrenia. Psychiatr Prax 34:223–229

    Article  PubMed  Google Scholar 

  • Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC (2002) The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63:856–865

    Article  PubMed  CAS  Google Scholar 

  • Yang LH, Chen TM, Yu ST, Chen YH (2007) Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. Pharmacol Res 56:202–208

    Article  PubMed  CAS  Google Scholar 

  • Yang Z, Yin JY, Gong ZC, Huang Q, Chen H, Zhang W, Zhou HH, Liu ZQ (2009) Evidence for an effect of clozapine on the regulation of fat-cell derived factors. Clin Chim Acta 408:98–104

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This work was supported by the Key Program of Science and Technology Department of Hunan Province, China (Grant No. 2012FJ086).

Conflict of interest

No conflict of interest was declared.

Author information

Authors and Affiliations

  1. Institute of Mental Health, the Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China

    Hu Yan & Jin-Dong Chen

  2. Department of Cardiology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China

    Xiao-Yan Zheng

Authors
  1. Hu Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jin-Dong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiao-Yan Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jin-Dong Chen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yan, H., Chen, JD. & Zheng, XY. Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia. Psychopharmacology 229, 1–7 (2013). https://doi.org/10.1007/s00213-013-3193-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-013-3193-7

Keywords

Search

Navigation